IntroductionThe prosthetic heart valves market has witnessed significant transformation over the past few decades, driven by ...

Analyst William Plovanic from Canaccord Genuity maintained a Hold rating on Edwards Lifesciences (EW – Research Report) and decreased the ...

Vanguard Group Inc made a significant addition to its portfolio by acquiring 9,018,094 shares of Edwards Lifesciences Corp ...

Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, provides products and technologies for structural ...

Edward Lifesciences' Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.

The Galien Foundation recently announced the nominees for its "Best Medical Technology" Pix Galien USA awards.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $81.0, with a high ...

Katie Szyman, who led Edwards Lifesciences Corp.’s Critical Care unit that was recently sold for $4.2 billion, says ...

Edwards Lifesciences (NYSE: EW), a medical technology company specializing in artificial heart valves, currently trades at $67 per share, about 50% lower than the peak level of $131 seen in December ...

EW saw its stock trading at around $95 in June 2022, just before the Fed started increasing rates, and it’s still trading 30% ...

Heart have announced rescheduled North American tour dates for early 2025. The updated itinerary comes after Heart postponed their remaining 2024 North American tour dates as singer Ann Wilson ...